gemcitabine has been researched along with 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Becker, D; Kendre, G; Kühnel, F; Lorz, G; Marhenke, S; Marquardt, JU; Murugesan, K; Pich, A; Poth, T; Reineke-Plaaß, T; Saborowski, A; Saborowski, M; Vogel, A; Wirtz, RM; Woller, N | 1 |
| Abou-Alfa, GK; Bekaii-Saab, TS; Bitzer, M; Borad, MJ; Borbath, I; El-Khoueiry, A; Goyal, L; Javle, M; Kelley, RK; Li, A; Macarulla, T; Moran, S; Pande, A; Philip, PA; Roychowdhury, S; Sadeghi, S; Shepherd, SP; Soifer, HS; Tanasanvimon, S; Waldschmidt, DT; Weiss, KH; Yong, WP; Zhu, AX | 1 |
1 trial(s) available for gemcitabine and 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea
| Article | Year |
|---|---|
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Central Serous Chorioretinopathy; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Dry Eye Syndromes; Fatigue; Female; Gemcitabine; Humans; Hyperphosphatemia; Male; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Pyrimidines; Radiation-Sensitizing Agents; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Retinal Detachment; Safety; Stomatitis; Treatment Outcome | 2021 |
1 other study(ies) available for gemcitabine and 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea
| Article | Year |
|---|---|
The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma.
Topics: Adenosylhomocysteinase; Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Proliferation; Cell Transformation, Neoplastic; Cholangiocarcinoma; Co-Repressor Proteins; Cyclic AMP Response Element-Binding Protein A; Deoxycytidine; Fetal Proteins; Gemcitabine; Gene Fusion; Liver Neoplasms, Experimental; Mice; Microtubule-Associated Proteins; Mutation; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Vesicular Transport Proteins | 2021 |